Beinaglutide
Overview
Beinaglutide is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist engineered with structural modifications to prolong plasma half-life and improve metabolic stability. The peptide activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while suppressing glucagon release, delaying gastric emptying, and promoting satiety. Its mechanism targets multiple pathways involved in glycemic control, making it suitable for the treatment of type 2 diabetes mellitus.
Key Research Findings
Beinaglutide received regulatory approval in China in 2019 for the treatment of type 2 diabetes based on domestic phase 3 trial data demonstrating significant HbA1c reductions and favorable weight effects. Published clinical evidence outside China remains limited, and the compound has not pursued regulatory pathways in the United States or European Union as of 2024.
Subcutaneous injection
FDA Approved
Interested in Beinaglutide?
Find a verified provider experienced with Beinaglutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Beinaglutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.